ADORA2A and neoplasm: Concurrent blocking of A2AR by its antagonist (inupadenant) and limiting intracellular eAdo concentration by EOS301984 synergizes with a PD-1 inhibitor, preventing tumor growth upon rechallenge in a humanized TNBC mice model (39).